Patents
Literature
39 results about "Molecular binding" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Molecular binding is an attractive interaction between two molecules that results in a stable association in which the molecules are in close proximity to each other.It is formed when atoms or molecules bind together by sharing of electrons. It often but not always involves some chemical bonding.
Method for screening for peptide using multiple libraries
PendingEP4768598A1Microbiological testing/measurementMicroorganism librariesCell freeMolecular binding
The present invention provides a method for screening for a candidate peptide capable of binding to a target molecule, the method including the steps of: (1) preparing a plurality of nucleic acid display libraries containing a barcoded peptide-nucleic acid complex, wherein the barcoded peptide-nucleic acid complex contains a nucleic acid moiety and a peptide moiety, the nucleic acid moiety contains a barcode sequence and a nucleic acid sequence encoding the peptide, and the plurality of nucleic acid display libraries are nucleic acid display libraries, each of which is independently produced by translation using a cell-free translation system; (2) mixing the plurality of nucleic acid display libraries to prepare a mixed nucleic acid display library; (3) bringing the mixed nucleic acid display library into contact with the target molecule; and (4) amplifying a nucleic acid corresponding to the nucleic acid moiety of the barcoded peptide-nucleic acid complex bound to the target molecule, using a barcode primer.
Owner:CHUGAI PHARMA CO LTD
Screening of CYP7A1 inhibitors and their application in the preparation of anti-hepatocellular carcinoma drugs
ActiveCN121583388Beasy to integratereduce infiltrationChemical property predictionMolecular designTumor targetMolecular binding
This application provides a method for screening inhibitors targeting CYP7A1 and their use in the preparation of anti-liver cancer drugs, relating to the field of tumor targeted drug design technology. The method for screening inhibitors targeting CYP7A1 protein includes: using the crystal structure of human cholesterol 7α-hydroxylase as a receptor model, precise docking screening is performed using software to screen drug-like molecules with molecular weights of 250-500 Da and lipid-water partition coefficients of -1 to 5 from a compound database; a graph neural network active learning model is used to predict and rank the protein-small molecule binding affinity of compounds in the database; the ΔG between candidate molecules and CYP7A1 is calculated using molecular mechanics / generalized Born surface area methods, with molecules having ΔG ≤ -40 kcal / mol considered potential inhibitors. The inhibitors of this application do not rely on the enzymatic activity of CYP7A1 to achieve anti-tumor effects and do not significantly affect cholesterol and bile acid metabolism levels.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
A photochemical chemiluminescence detection reagent, a preparation method thereof and a procalcitonin detection method
The application provides a photochemical chemiluminescence detection reagent and a preparation method thereof, and a procalcitonin detection method. The photochemical chemiluminescence detection reagent comprises acceptor microspheres and donor microspheres; wherein the acceptor microspheres are carboxyl-modified acceptor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody; and the donor microspheres are carboxyl-modified donor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody. The photochemical chemiluminescence detection reagent has higher stability in various environments, can more accurately combine with target molecules, realizes more efficient detection and recognition, and enables the microspheres to more accurately capture and fix the target molecules, so as to perform subsequent luminescence reaction. The detection method has high sensitivity and a wide range, can be used as a detection reagent for diagnosing and identifying infectious diseases of individuals, and has application value.
Owner:GUANGDONG PHARMA UNIV +1
Methods of predicting tumor neoantigens of endogenous retroviral origin
This invention provides a method for mining tumor antigens derived from endogenous retroviruses. The method involves bulk RNA-seq sequencing of tumor tissue and adjacent normal tissue samples using a splicing strategy to obtain DNA sequences of human endogenous retrovirus (HERV)-derived transcripts (hervRNA). Subsequently, a specific screening strategy is employed to obtain candidate open reading frames (ORF) sequences on tumor-specific hervRNAs. Finally, homology analysis, prediction of binding energy to human leukocyte antigen class I (HLA-I) molecules, and multi-site analysis are used to predict and mine neoantigens derived from HERV in tumors.
Owner:SHANGHAI JIAOTONG UNIV
Secretion product evaluation method and secretion product evaluation system
PCT designated stageWO2026115815A1Microbiological testing/measurementImmunoglobulinsAntigenMolecular binding
Provided is a technique capable of evaluating a property of a secretion product with high accuracy. Specifically provided are a secretion product evaluation method and others, the secretion product evaluation method comprising: a positional information identification step for identifying positional information of at least one secretory cell and at least one antigen-holding particle on the basis of optical information relating to a carrier that holds the secretory cell and the antigen-holding particle; a secretion product information acquisition step for acquiring information relating to a secretion product that binds to a binding target molecule held by the secretory cell and the antigen-holding particle; and a secretion product evaluation step for evaluating a property of the secretion product on the basis of the positional information and the information relating to the secretion product.
Owner:SONY GROUP CORP
Methods and related aspects for molecular tracking and analysis
Provided herein are methods of determining molecular binding kinetics on particles, such as magnetic nanoparticles. In some embodiments, the methods include introducing an incident light from a light source toward a sample container that comprises a particle-bound biomolecule-ligand composition comprising a plurality of particle-bound biomolecules and a plurality of ligands that binds, or is capable of binding, to biomolecules of the plurality of particle-bound biomolecules, detecting light scattered from particle-bound biomolecule-ligand complexes in the particle-bound biomolecule-ligand composition over a duration to produce a set of imaging data using the detector, and determining size or volume changes of one or more of the particle-bound biomolecule-ligand complexes during at least a portion of the duration from the set of imaging data to thereby determine the molecular binding kinetics on the particles. Related systems and computer readable media are also provided.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Methods for identifying compounds that bind to target molecules using mirror images of the target molecule.
Owner:AKERS-CHEMICAL CO
A recombinant Staphylococcus aureus nanoparticle protein HI-mi3, its preparation method and application
This invention provides a recombinant Staphylococcus aureus nanoparticle protein HI-mi3, its preparation method, and its applications. This protein is composed of HI (containing the key SA virulence factor α-hemolysin Hla). H35L The fusion protein HI and mi3 are composed of the N2 functional domain of the iron ion surface determinant B and self-assembled nanoparticle protein mi3. This invention uses the SpyTag / SpyCatCher protein coupling system to link the fusion protein antigen HI and mi3, obtaining the Staphylococcus aureus self-assembled nanoparticle protein HI-mi3. Both the recombinant protein SpyCatcher-mi3 and the recombinant protein SpyTag-HI of this invention are induced to be expressed in soluble form in Escherichia coli. The recombinant protein SpyCatcher-mi3 of this invention can covalently bind to the recombinant protein SpyTag-HI via isopeptide bonds to form the HI-mi3 nanoparticle vaccine molecule, with simple binding conditions. The HI-mi3 nanoparticle vaccine of this invention can induce a high level of immune response in animals and exert an immunoprotective effect.
Owner:ARMY MEDICAL UNIV
Method and system for binding affinity prediction and method of generating a candidate protein-binding peptide
In a first aspect of the present disclosure, there is provided a computer-implemented method of predicting a binding affinity of a query binder molecule to a query target molecule, the query binder molecule having a first amino acid sequence and the query target molecule having a second amino acid sequence, the method comprising: computing, with the at least one processor, the binding affinity for the query binder molecule to the query target molecule as a weighted combination of reference binding values of reference binder-target subsequence pairs, wherein weights of the weighted combination are based on similarity scores.
Owner:NEC ONCOIMMUNITY AS
Peptide screening methods
To provide a method for efficiently selecting peptides that have high affinity for target molecules and that also possess functional properties. [Solution] A method for screening peptides, comprising the following steps. (1) A step of reacting a functional crosslinking agent with a peptide to form a peptide complex having a structure in which the peptide and the functional crosslinking agent are crosslinked intermolecularly. (2) A step of mixing the peptide complex obtained in step (1) with the target molecule and selecting the peptide complex bound to the target molecule.
Owner:KANEKA CORP
Evanescent scattering imaging of single molecules
ActiveUS12638391B2Method using image detector and image signal processingScattering properties measurementsMetal coatingLight irradiation
Provided herein are methods of detecting single molecules that include binding single molecules in a sample solution to a first surface of an optically transparent substrate include the optically transparent substrate is free of a metallic coating. In some embodiments, the methods include irradiating the first surface of the substrate with an incident light having an incident angle selected to achieve total internal reflection of the incident light, thereby scattering light from the first surface and from the single molecules bound to the surface in which a wavelength of the incident light is between 10 nm and 350 pm and the optically transparent substrate has a refractive index at the wavelength of the incident light exceeding that of the sample solution, and collecting an image that captures interference between evanescent light scattered from the single molecules and the first surface. Systems and additional methods are also provided.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Method for selecting high-affinity compounds for target molecules
Owner:KANEKA CORP
Estimation system, method for estimating molecular conformation, and estimation program
PendingEP4769418A1ChemoinformaticsComputational theoretical chemistryChemical physicsMolecular binding
An estimation system comprises at least one processor. The at least one processor acquires a target molecule model representing a conformation of a target molecule, generates a molecule-of-interest model representing a conformation of a molecule of interest, the molecule of interest being a molecule capable of binding to the target molecule, calculates energy of interaction between the molecule of interest and the target molecule as intermolecular interaction energy based on a positional relationship between the target molecule model and the molecule-of-interest model, calculates energy of interaction in the molecule of interest as intramolecular interaction energy, and estimates a conformation of the molecule of interest based on the intermolecular interaction energy and the intramolecular interaction energy.
Owner:CHUGAI PHARMA CO LTD
Bispecific antibody targeting TIM3 and use thereof
ActiveUS12662534B2Biological material analysisAntibody ingredientsAntiendomysial antibodiesNatural Killer Cell Inhibitory Receptors
The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC (NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.
Owner:L&L BIO CO LTD NINGBO CHINA
Antibacterial application of pyrrolidin-piperdine derivatives containing composition to inhibit helicobacter pylori replication, preparation method thereof
: Title: Antibacterial Application of Pyrrolidin-Piperdine Derivatives Containing Composition to Inhibit Helicobacter Pylori Replication, Preparation Method Thereof The present disclosure proposes a method for identification, optimizing, and preparing a therapeutic molecule (MA01027) for inhibiting cytotoxin-associated gene A (CagA) protein of Helicobacter pylori. The therapeutic molecule specifically targets and binds to a particular protein of interest, thereby enhancing the efficacy and specificity of the treatment. The therapeutic molecule is optimized for its binding affinity and selectivity for the target protein. The therapeutic molecule involves combining specific reactants under controlled conditions to achieve high yields and purity of the therapeutic molecule. The therapeutic molecule preparation includes purification steps to isolate the therapeutic molecule from the reaction mixture using standard techniques, thereby ensuring a high-quality final product. The therapeutic molecule binds to the CagA protein of H. pylori, inhibiting its replication by more than 90% and eliminating H. pylori-associated hemolysis.
Owner:AGGUNNA MADHUMITA +1
Combined preparations for the treatment of cancer or infection
Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.
Owner:IMMUTEP SAS
A method for monitoring the inhibitory effect of small molecule drugs in real time
PendingCN122259522AMicrobiological testing/measurementFluorescence/phosphorescenceProtein moleculesMolecular binding
This invention discloses a method for real-time monitoring of the inhibitory effect of a small molecule drug, vorinostat, comprising the following steps: constructing a fluorescence confocal electrochemical impedance microscopy imaging system using a WS2 chip as the working electrode; immobilizing probe protein molecules on the surface of the WS2 chip; applying an electrical signal to the WS2 chip after probe protein molecule immobilization, and monitoring the inhibitory effect of the small molecule drug by the change curve of the amplitude signal over time. In this invention, when the small molecule drug binds to the probe protein molecules immobilized on the WS2 surface, the surface charge of the WS2 changes, and the inhibitory effect of the small molecule drug on the probe protein molecules is monitored by the change of the WS2 fluorescence signal.
Owner:YANSHAN UNIV
Staining test control substance, staining test slide prepared using the same, staining test control substance preparation kit, and method for manufacturing staining test control substance
PendingCN122122464ACell receptors/surface-antigens/surface-determinantsOvalbuminStainingControl substances
In a control substance used in a control test in a staining examination, a slide prepared using the same, and a manufacturing method thereof, in order to provide a control substance capable of being easily prepared, a slide prepared using the same, the following configuration is adopted. A control substance for staining examination, comprising a target molecule that specifically binds to a substance contained in a staining reagent, a negatively charged charged molecule, and a binding substance that binds the target molecule and the charged molecule.
Owner:HITACHI HIGH TECH CORP
Antisense nucleic acid targeting APOC3
The present invention provides an antisense oligomer having the base sequence depicted in SEQ ID NO: 26, an antisense oligomer having a base sequence resulting from substitution, deletion, insertion, or addition of 1 to 6 bases in the base sequence depicted in SEQ ID NO: 26, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable hydrate thereof, an oligonucleotide conjugate in which the antisense oligomer is bound with a molecule capable of binding to an asialoglycoprotein receptor, and a pharmaceutical composition containing the same.
Owner:NAT CEREBRAL & CARDIOVASCULAR CENT +1
Viral peptides and uses thereof
The present disclosure provides isolated peptides derived from human T-lymphotropic virus type 1 (HTLV-1), peptide-based molecules (e.g., peptide-MHC (pMHC) complexes), polynucleotides and vectors encoding the peptides or peptide-based molecules, pharmaceutical compositions (e.g., vaccine compositions), and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides binding moieties that bind to the peptides or peptide-based molecules disclosed herein, and their use for treating, preventing, and / or reducing the likelihood of HTLV-1 infection and / or HTLV-1-induced disease. The present disclosure also provides methods and systems for identifying immunogenic virus-derived peptides.
Owner:REGENERON PHARMACEUTICALS INC
Methods for structure determination using antibodies
Provided herein is a method of determining a high resolution structure of a molecule, the method comprising: determining a high resolution structure of a complex comprising the molecule and an antibody or antigen binding fragment thereof or antibody scaffold bound to the molecule, wherein the antibody or antigen binding fragment comprises one or more engineered disulfide bonds that increase the conformational rigidity of the antibody or antigen binding fragment thereof or the antibody scaffold; and determining a high resolution structure of the molecule from cryo-EM thereby.
Owner:GENENTECH INC
Theoretical calculation assisted screening of eutectic solvent extraction of naringin and application thereof
PendingCN122344224ANaringinPharmacologic action
The application discloses a naringin high-efficiency extraction process optimization and multi-dimensional biological activity research method based on a low eutectic solvent. Through systematic screening of 11 kinds of low eutectic solvents (Deep Eutectic Solvents, DESs) and 2 kinds of traditional organic solvents on the extraction efficiency of naringin, it is determined that the low eutectic solvent composed of tetraethyl ammonium bromide and 1,2-propanediol is the optimal solvent, the extraction process parameters are optimized through single factor experiment and response surface method, and the optimal extraction conditions of naringin are obtained. The extracted naringin is subjected to antioxidant and antibacterial activity detection, the MoGAPI method is used for life cycle assessment of the extraction process, and through network pharmacology and molecular docking technology, the potential action target, signal pathway and molecular binding mechanism of naringin in treating gastric cancer are explored. The method is high in extraction efficiency, green in environmental protection and safe in operation, and further systematically clarifies the multi-dimensional biological activity and potential pharmacological action of naringin, thereby providing reliable process and theoretical support for the green industrialized production and subsequent development and application of naringin.
Owner:SHANDONG UNIV OF SCI & TECH
RNA-small molecule binding affinity prediction method based on multi-view learning
PendingCN122090955Areduce imbalanceSolve the problem of insufficient extractionBiostatisticsInstrumentsData setMolecular binding
The invention belongs to the field of intelligent biological prediction, and particularly relates to an RNA-small molecule binding affinity prediction method based on multi-view learning. The method comprises three stages of data set up and down sampling processing, feature construction and extraction based on RNA and small molecule sequences, and binding affinity prediction. According to the method, data set distribution is optimized through an up-down sampling method, multi-view feature information is constructed through sequence information of RNA and small molecules, a deep network is established to extract and depth biological information features, and finally, an MLP regression device is adopted to predict an RNA-small molecule binding affinity value, so that drug discovery work is assisted to be achieved. In order to solve the problem of imbalance of the existing data set, the invention provides a method of combining up and down sampling for processing, and the problem of imbalance is effectively relieved.
Owner:JIANGNAN UNIV
A no-wash, multiplexable competitive immunoassay method
This invention provides a wash-free, competitive immunoassay method capable of simultaneous multiplex detection. Specifically, this invention utilizes self-developed Raman microspheres (R-Sphere) with non-overlapping Raman signals to conjugate specific antibodies against the target molecule onto the Raman microspheres. The target molecule is then detected through an immunoassay. Raman microsphere-antibody conjugates that do not bind to the target molecule are adsorbed onto the container wall via carboxyl magnetic beads, thereby eliminating background signal interference. This method offers advantages such as wash-free operation, separation-free operation, ease of use, high accuracy, and the ability to simultaneously detect multiple signals.
Owner:XINJIANG MEDICAL UNIV +2
Bispecific antibodies and their applications
This invention proposes a bispecific antibody and its application. The antibody comprises: a first antigen-binding region having 4-1BB molecule binding activity; and a second antigen-binding region having BCMA molecule binding activity. The bispecific antibody prepared by this invention can simultaneously target 4-1BB and BCMA, thereby mediating the killing of tumor cells by T cells and exhibiting strong tumor-suppressive ability.
Owner:HEFEI TG IMMUNOPHARMA CO LTD
PD-1 molecule for blocking binding of Anti-PD-1 antibody to PD-1 molecule on cell surface, and mutant and use thereof
Provided are a PD-1 molecule for blocking the binding of an anti-PD-1 antibody to a PD-1 molecule on a cell surface, and a mutant and the use thereof. Further provided is a protein molecule, which has 80-100% sequence identity to a wild-type protein as shown in SEQ ID NO: 1. The provided recombinant protein H126 and H134 molecules can competitively bind to an anti-PD-1 antibody drug with the endogenous PD-1 molecule expressed by a T cell, without affecting the binding of PD-1 to an endogenous PD-L1 molecule, thereby restoring the function suppression on activated T cells and alleviating the symptoms of immunotherapy-related adverse events. By means of the protein molecule, a new way of performing clinical treatment of the immunotherapy-related adverse events is provided.
Owner:SHENZHEN PREGENE BIOPHARMA CO LTD
Selective digital multiplexing
This invention provides a method for detecting molecular targets using digital PCR (dPCR) with a blocking agent targeting non-target molecules. A mixture of unique probes is provided for each target. The blocking agent binds to the non-target molecule and prevents it from fluorescing from a partition. The fluorescence intensities of two or more colors are read, and the intensities are plotted as a 2D graph. In this graph, different targets contribute to well-distinguishable clusters. Each cluster in the graph exists substantially along its own radius, thus allowing for radial multiplexing. The use of the blocking agent allows for selection of non-target molecule detection and improves the resolution of radial multiplexing, thereby allowing the detection of multiple targets.
Owner:BIO RAD LABORATORIES INC
Application of aluminum-based alloy material in photocatalytic synthesis of ammonia reaction
PendingCN122164404ACatalyst activation/preparationEnergy based chemical/physical/physico-chemical processesMolecular bindingAlloy
This invention relates to the application of an aluminum-based alloy material in the photocatalytic ammonia synthesis reaction. The invention prepares an aluminum-based alloy material by reacting Al with metal M at a specific heat treatment temperature, and for the first time applies this material to the photocatalytic ammonia synthesis reaction. On one hand, it utilizes the electronic regulation effect of aluminum on metal M to promote the adsorption and activation of N2 molecules by metal M; on the other hand, it utilizes aluminum as a second active site to capture nitrogen species overflowing from metal M under illumination, forming weak adsorption sites that promote subsequent hydrogenation and the desorption of the product NH3. This dual-site catalytic strategy cleverly avoids the scaling relationship in ammonia synthesis, greatly enhancing catalytic activity. Furthermore, this invention selects a specific metal M with strong binding ability to N2 molecules, utilizing its ability to promote N2 molecule activation, which is beneficial to the ammonia synthesis reaction, thereby significantly improving the catalytic activity of the aluminum-based alloy material.
Owner:SHANGHAI JIAOTONG UNIV
Pharmaceutical compositions for delivery to the eye
Aptamers are single-stranded RNA or DNA molecules that bind to target molecules by forming complex three-dimensional structures. Their target molecules vary widely—including proteins, peptides, carbohydrates, lipids, small compounds, and metal ions—and because of their strong binding affinity and high specificity, aptamers have been put to practical use in fields such as therapeutics, diagnostics, and separation technologies. As pharmaceuticals, the world's first aptamer drug, Macugen®, was approved in the United States in 2004 as a treatment for neovascular age-related macular degeneration, and several other aptamers are now in clinical development. Research is also progressing on their use as tools in drug delivery systems (DDS), and the importance of aptamers in the pharmaceutical field is expected to continue growing. In this article, we provide an overview of aptamer acquisition methods and optimization strategies for therapeutic use, and introduce the latest developments in aptamer-based drugs currently in clinical trials.
Owner:ASTELLAS US LLC